Page 1

it Immuneering Immuneering Reports Second Quarter 2021 Financial Results and Provides Business Updates September 9 , 2021 Recently completed upsized initial public offering raising $ 129.4 million in gross proceeds , providing runway into 2024 Company expects to file IND for IMM - 1-104 in Q1 2022 CAMBRIDGE , Mass . , Sept. 09 , 2021 ( GLOBE NEWSWIRE ) -- Immuneering Corporation ( Nasdaq : IMRX ) , a biopharmaceutical company advancing a robust pipeline of oncology and neuroscience product candidates that are designed to uniquely disrupt cellular signaling dynamics , today reported financial results for the second quarter ended June 30 , 2021 and provided a corporate update . " We continue to make significant progress across all aspects of our organization and with the recent IPO proceeds and the additions to our management team and board of directors , we plan to advance our pipeline and strive to bring novel medicines to patients , " said Ben Zeskind , chief executive officer of Immuneering Corporation . " In the near term , we remain focused on continuing to advance IMM - 1-104 , our RAF - MEK inhibitor , targeting RAS mutant tumors into the clinic and anticipate filing our IND in Q1 2022. " Corporate Highlights • Completed Initial Public Offering : On August 3 , 2021 , Immuneering announced the closing of its upsized initial public offering of 8,625,000 shares of Class A common stock , including the full exercise by the underwriters of their overallotment option to purchase 1,125,000 shares of Class A common stock , at a public offering price of $ 15.00 per share , for total gross proceeds of approximately $ 129.4 million , before deducting underwriting discounts , commissions and estimated offering expenses payable by Immuneering . • Strengthened Leadership Team : Immuneering further strengthened its management team with the appointment of Biren Amin as its Chief Financial Officer in April 2021 and Michael Bookman as the company's General Counsel and Secretary in July 2021 . • Enhanced and Expanded Board of Directors : Immuneering also welcomed new additions to the board of directors with the appointments of Laurie Keating in April 2021 , and Ann Berman in July 2021 . • Completed Series B Financing in 1H 2021 : Immuneering raised $ 62 million in a Series B financing led by Cormorant Asset Management , Surveyor Capital Citadel company ) , Rock Springs Capital , funds and accounts advised by T. Rowe Price Associates , Inc. , funds and accounts managed by Blackrock , Perceptive Advisors , and LYFE Capital . Key Development Highlights • IMM - 1-104 IND submission expected in Q1 2022 : Immuneering expects to file the IND for IMM - 1-104 in Q1 2022 and expects to start its Phase 1 trial evaluating IMM - 1-104 in 1H 2022. IMM - 1-104 is a highly selective dual - MEK inhibitor that has been designed to overcome MAPK - feedback loops and exhibits deep cyclic inhibition through its targeted potency and short half - life . As a result , Immuneering believes IMM - 1-104 can target patients with a broad spectrum of mutations , such as KRAS and NRAS , that activate the MAPK pathway . Second Quarter 2021 Financial Highlights • Cash Position : Cash and cash equivalents as of June 30 , 2021 were $ 50.2 million , compared with $ 37.1 million as of December 31 , 2020. The June 30 , 2021 cash and equivalents excludes $ 118.3 million in net proceeds from the Company's initial public offering , which was completed in August 2021 . • Research and Development ( R & D ) Expenses : R & D expenses for the second quarter of 2021 were $ 7.0 million , compared with $ 3.2 million for the second quarter of 2020. The increase in R & D expenses was primarily attributable to higher preclinical costs related to the Company's lead programs and increased personnel to support ongoing research and development activities . • General and Administrative ( G & A ) Expenses : G & A expenses for the second quarter of 2021 were $ 1.3 million , compared with $ 0.6 million for the same period of 2020. The increase in G & A expenses was primarily attributable to an increase in headcount in our general and administrative functions to support the Company's business and to costs related to preparing for the Company's initial public offering . • Net Loss : Net loss attributable to common stockholders was $ 7.9 million , or $ 1.61 per share , for the quarter ended